Pressmeddelanden, rapporter och bolagsmeddelande för Eevia Health Plc

Eevia Health Plc's Board of Directors has announced plans for a rights issue of shares, offering existing shareholders preferential rights to subscribe, with a maximum amount of approximately SEK 12.1 million before transaction costs. This initiative aims to support the company's strategic reorientation and turnaround plan. The rights issue requires authorization from an extraordinary general meeting scheduled for January 17, 2025. External investors have secured about 27% of the rights issue through underwriting commitments. To maintain operations until the completion of the rights issue, Eevia has secured a EUR 200,000 bridge loan. Shareholders will receive one subscription right per share held, allowing them to subscribe for two new shares at an expected price of SEK 0.09 per share. The subscription period varies between Sweden and Finland, running from late January to mid-February 2025. The company will issue an information document in place of a prospectus for the rights issue.

Shareholders of Eevia Health Abp are invited to an Extraordinary General Meeting on January 17, 2025, at 12:00 Finnish time, at the company's main office in Seinäjoki, Finland. Registration and voting ticket distribution will begin at 11:00. The meeting agenda includes opening the meeting, electing officials, verifying meeting legality and attendance, and authorizing the Board of Directors to issue shares, options, and special rights up to 180 million shares, valid until June 30, 2025. This authorization replaces the previous one from June 5, 2024. Meeting documents and proposals are available on Eevia Health's website. Shareholders must register by January 14, 2025, and provide necessary identification details. Holders of nominee-registered shares and shares registered with Euroclear Sweden AB must follow specific registration procedures. Shareholders can participate via proxy with appropriate documentation. On December 30, 2024, Eevia Health had 67,055,595 shares, each granting one vote. Eevia Health, founded in 2017, produces bioactive compounds from plant materials and operates a green-chemistry facility in Finland. The company is listed on the Spotlight Stock Market in Sweden. For more information, contact CEO Stein Ulve.

Eevia Health Plc announced that it has decided to terminate its letter of intent with Stemtech Corporation, thereby abandoning the proposed reverse takeover. After careful consideration, Eevia's Board of Directors concluded that it is in the best interest of the company and its stakeholders to focus on its own strategic business plans rather than pursuing the complex and costly merger with Stemtech, which also posed a high risk of not being able to relist on the Spotlight Stock Market. Eevia will now concentrate on its Arctic polyphenol products, which are expected to drive significant revenue growth. Eevia Health, founded in 2017, specializes in bioactive compounds extracted from wild-harvested plants in Finland and Sweden, and it operates a green-chemistry production facility.

Eevia Health has received a blanket sales order valued at MSEK 1,849 (KUSD 169) for its elderberry extract, Feno-Sambucus™ 7 ORGANIC, from Select Ingredients, a distributor based in San Diego, California. This distributor focuses on organic ingredients and serves customers in major US states. The end customer operates in the rapidly growing whole foods and drinks sector across North America. Feno-Sambucus™ 7 ORGANIC is noted for its immune-modulating properties and enhanced bioactivity due to Eevia's production methods. The order will be fulfilled in several stages over the coming months and is a repeat order, with expectations for future repeats. Eevia Health, founded in 2017, produces bioactive compounds from wild-harvested plant materials, primarily from Finnish and Swedish forests. The company emphasizes sustainability and operates a green-chemistry production facility in Finland. Eevia Health is listed on the Spotlight Stock Market in Sweden.

Eevia Health Plc has approved a new strategic business and turnaround plan for 2025-2026, revising its financial targets. Following an analysis, the company aims for a revenue of MEUR 3 and an EBITDA of KEUR 100 in 2025, and a revenue of MEUR 5 with an EBITDA of MEUR 1 in 2026. These targets are set conservatively, but the company sees potential for better performance. Eevia Health, founded in 2017, produces bioactive compounds from wild-harvested plant materials in Finland and Sweden. The company is listed on the Spotlight Stock Market in Sweden. For more information, contact CEO Stein Ulve or visit their website.

Eevia Health Plc has announced a delay in publishing its Interim Report for the third quarter, now scheduled for release on November 29, 2024. This postponement is due to the onboarding of a new Board and an unforeseen urgent project that requires significant attention. The new Board was elected on November 4 and is still in the process of being inducted. The next Board meeting on November 20 will focus on this urgent project, necessitating more time for the review of the Interim Report. Eevia Health, founded in 2017, produces bioactive compounds from plant materials, primarily sourced from Finnish and Swedish forests. The company operates a green-chemistry production facility in Finland and is listed on the Spotlight Stock Market in Sweden. For more information, contact Stein Ulve, CEO, via email or phone.

Eevia Health Plc has received a 51,000 euro sales order from a European nutraceutical brand owner based in Sweden. The customer, which markets herbal dietary supplements and cosmetics in over 50,000 retail outlets across 38 countries, including China and the USA, has placed a repeat order for Feno-Myrtillus® 1, a bilberry extract standardized for anthocyanins. Eevia was chosen for its high quality and product authenticity. Founded in 2017, Eevia Health produces bioactive compounds from plant materials, primarily wild-harvested from Finnish and Swedish forests, and sells them as ingredients for dietary supplements globally. The company operates a green-chemistry production facility in Finland and is listed on the Spotlight Stock Market in Sweden.

Eevia Health Plc announced a correction regarding its earlier press release about negotiations with a European food manufacturer for a new plant extract product. Initially expected to significantly boost Eevia's revenue and profits in 2025, the project has faced delays due to cost and other issues, leading to a lack of significant volume commitments for 2025. The parties are now discussing single orders on a case-by-case basis, with a new order anticipated for December. Eevia has proposed a new technology to reduce costs, but no commercial contract for larger volumes has been agreed upon. Eevia does not expect significant order commitments in 2025 but remains open to future participation in the project. Eevia Health, founded in 2017, specializes in bioactive plant extracts, primarily sourced from wild-harvested materials in Finland and Sweden. The company operates an eco-friendly production facility in Finland and is listed on the Spotlight Stock Market in Sweden.

Eevia Health PLC received several sales orders totaling KEUR 56 from European and Asian customers. Orders include KEUR 18 from distributor Breko for various organic extracts, KEUR 21 from a Swedish nutraceutical brand, KEUR 9 from Finnish customers, and KEUR 8 from a regular customer in Taiwan. The products ordered are in stock and beneficial for operational cash flow. Eevia Health, founded in 2017, produces bioactive compounds from wild-harvested plant materials in Finland and Sweden. The company manufactures 100% organically certified plant extracts used in dietary supplements and food brands globally. Eevia operates a green-chemistry production facility in Finland, emphasizing sustainability and transparency. For more information, contact Stein Ulve, CEO, at stein.ulve@eeviahealth.com or investor@eeviahealth.com, or call +358 400 22 5967.

Stein Ulve, CEO of Eevia Health Plc, has purchased 525,700 shares in the company through a recent Rights issue, at a price of EUR 0.05 per share, totaling EUR 26,285. Before this purchase, Ulve held 2,284,714 shares, representing 6.40% of the outstanding shares. Now, he holds 2,810,414 shares, which equals 3.55% of the current outstanding shares due to dilution from the Rights issue. Ulve also received 131,425 Warrants TO1 as part of the subscription, with the subscription period set for August 2025. Eevia Health Plc, founded in March 2017, produces bioactive compounds from wild-harvested plant materials, primarily from Finnish and Swedish forests. The company is listed on the Spotlight Stock Market in Sweden. For more information, visit www.eeviahealth.com.